How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

888 results for

Fibrin Degradation Products

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography? (PubMed)

Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography? Elevated d-dimers in injured patients with paradoxically low fibrinolysis activity measured by viscoelastic assays have been speculated to be "occult" fibrinolysis. However, an alternative explanation is that these patients have previously activated their fibrinolytic system and have shut it down by the time of blood (...) < 0.001). The DFI patients had increased rates of massive transfusion (33% vs 3.3%; p < 0.001) and mortality (40% vs 6.2%; p < 0.001). Among DFI patients, TXA significantly improved fibrin clot strength with hyperfibrinolysis (+19% clot strength; p < 0.001) but not with shutdown (+1.2%) or physiologic (-2.5%).Patients with DFI have multiple abnormalities of their coagulation system, but only DFI patients with hyperfibrinolysis have improved fibrin clot strength with TXA.Copyright © 2019. Published

2019 Journal of the American College of Surgeons

2. Plasma Fibrin Degradation Product and D-Dimer Are of Limited Value for Diagnosing Periprosthetic Joint Infection. (PubMed)

Plasma Fibrin Degradation Product and D-Dimer Are of Limited Value for Diagnosing Periprosthetic Joint Infection. Although the Musculoskeletal Infection Society introduced the use of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as inflammatory markers for diagnosing periprosthetic joint infection (PJI), no single blood marker reliably detects infection before revision arthroplasty. We therefore posed 2 questions: (1) Are fibrin degradation product (FDP) and D-dimer of value

2019 Journal of Arthroplasty

3. Neutrophil Elastase-Derived Fibrin Degradation Products Indicate Presence of Abdominal Aortic Aneurysms and Correlate with Intraluminal Thrombus Volume. (PubMed)

Neutrophil Elastase-Derived Fibrin Degradation Products Indicate Presence of Abdominal Aortic Aneurysms and Correlate with Intraluminal Thrombus Volume. The intraluminal thrombi (ILT) of abdominal aortic aneurysms (AAA) contain neutrophils, which can secrete elastase. We evaluated whether plasma neutrophil elastase-derived cross-linked fibrin degradation products (E-XDP) could reveal the presence, size and mechanical stress of AAAs and its ILTs.E-XDP and D-dimer were measured in plasma from 37

2018 Thrombosis and haemostasis

4. Diagnostic implication of fibrin degradation products and D-dimer in aortic dissection (PubMed)

Diagnostic implication of fibrin degradation products and D-dimer in aortic dissection Fibrin degradation products (FDP) and D-dimer have been considered to be involved in many vascular diseases. In this study we aimed to explore the diagnostic implication of FDP and D-dimer in aortic dissection patients. 202 aortic dissection patients were collected as the case group, 150 patients with other cardiovascular diseases, including myocardial infarction (MI, n = 45), pulmonary infarction (n = 51

Full Text available with Trip Pro

2017 Scientific reports

5. What are diagnostic implications and limitations of assessing D-dimer and fibrin degradation products levels in the management of patients with acute aortic dissection? (PubMed)

What are diagnostic implications and limitations of assessing D-dimer and fibrin degradation products levels in the management of patients with acute aortic dissection? 28932507 2018 11 13 2072-1439 9 8 2017 Aug Journal of thoracic disease J Thorac Dis What are diagnostic implications and limitations of assessing D-dimer and fibrin degradation products levels in the management of patients with acute aortic dissection? 2214-2216 10.21037/jtd.2017.07.05 Akutsu Koichi K Division of Vascular

Full Text available with Trip Pro

2017 Journal of thoracic disease

6. Diagnostic implication of fibrin degradation products and D-dimer in aortic dissection—author’s reply (PubMed)

Diagnostic implication of fibrin degradation products and D-dimer in aortic dissection—author’s reply 29268441 2018 11 13 2072-1439 9 10 2017 Oct Journal of thoracic disease J Thorac Dis Diagnostic implication of fibrin degradation products and D-dimer in aortic dissection-author's reply. E941-E942 10.21037/jtd.2017.09.06 Li Shuangshuang S Department of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. Dong Jian J Department of Vascular Surgery

Full Text available with Trip Pro

2017 Journal of thoracic disease

7. Re-visiting D-dimers and fibrin degradation products for the diagnosis of acute aortic dissection (PubMed)

Re-visiting D-dimers and fibrin degradation products for the diagnosis of acute aortic dissection 28839953 2018 11 13 2072-1439 9 7 2017 Jul Journal of thoracic disease J Thorac Dis Re-visiting D-dimers and fibrin degradation products for the diagnosis of acute aortic dissection. 1744-1747 10.21037/jtd.2017.06.23 Luo Chwan-Yau CY Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Full Text available with Trip Pro

2017 Journal of thoracic disease

8. Fibrin/fibrinogen degradation products (FDP) at hospital admission predict neurological outcomes in out-of-hospital cardiac arrest patients. (PubMed)

Fibrin/fibrinogen degradation products (FDP) at hospital admission predict neurological outcomes in out-of-hospital cardiac arrest patients. This study aimed to test the hypothesis that coagulation, fibrinolytic markers and disseminated intravascular coagulation (DIC) score (International Society on Thrombosis and Haemostasis) at hospital admission of out-of-hospital cardiac arrest (OHCA) patients can predict neurological outcomes 1 month after cardiac arrest.In this retrospective (...) levels of fibrinogen, D-dimer, fibrin/fibrinogen degradation products (FDP), and antithrombin; and calculated DIC score. Favorable neurological outcomes were defined as a cerebral performance category 1-2.We analyzed data for 315 patients. Except for fibrinogen level, all coagulation variables, fibrinolytic variables, and DIC score were associated with favorable neurological outcomes. In the receiver operating characteristic curve analysis, FDP level had the largest area under the curve (AUC; 0.795

Full Text available with Trip Pro

2016 Resuscitation

9. Elevated Levels of Serum Fibrin and Fibrinogen Degradation Products Are Independent Predictors of Larger Coronary Plaques and Greater Plaque Necrotic Core (PubMed)

Elevated Levels of Serum Fibrin and Fibrinogen Degradation Products Are Independent Predictors of Larger Coronary Plaques and Greater Plaque Necrotic Core Co-existence of vulnerable plaque and pro-thrombotic state may provoke acute coronary events. It was hypothesized that elevated serum levels of fibrin and fibrinogen degradation products (FDP) are associated with larger total plaque and necrotic core (NC) areas.Seventy-five patients presenting with stable anginal symptoms (69%) or stabilized

Full Text available with Trip Pro

2016 Circulation journal : official journal of the Japanese Circulation Society

10. Fibrin Degradation Products

Fibrin Degradation Products Fibrin Degradation Products Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Fibrin Degradation Products (...) Fibrin Degradation Products Aka: Fibrin Degradation Products , FDP From Related Chapters II. Normal Range: <10 ug/ml III. Increased (DIC) Primary Severe liver disease IV. False positive (RF) present Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Fibrin Degradation Products." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Fibrin split products

2018 FP Notebook

11. Mast cell chymase degrades fibrinogen and fibrin. (PubMed)

analysed by direct immunofluorescence.Chymase-positive mast cells were associated with fibrin-positive vessels in vasculitis cryosections. Rh-chymase degraded the alpha-, beta- and gamma-chains of fibrinogen, while heparin enhanced the degradation of the beta-chain. Rh-chymase pretreatment of fibrinogen prolonged thrombin-induced clotting time. Fibrinogen degradation products induced by rh-chymase increased the clotting time of human plasma. Rh-chymase degraded fibrin gel prepared from fibrinogen (...) Mast cell chymase degrades fibrinogen and fibrin. The accumulation of immunoreactants and fibrinoid necrosis of postcapillary vessel walls are common pathological features of cutaneous immune complex vasculitis. In more advanced lesions, these immunoreactants are subject to proteolysis. Mast cell chymase is a powerful enzyme that can degrade several substrates including the extracellular matrix. Heparin can influence the catalytic properties of chymase.To study the effects of recombinant human

2018 British Journal of Dermatology

12. Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products (PubMed)

Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products Fibrin degradation results in the formation of fibrin degradation products (FDPs) of different molecular weights, which include D-dimer. Commercial D-dimer assays recognize multiple forms of FDP with different specificity. As a result, the absence of an international D-dimer standard and the marked discrepancy in the D-dimer values in the same samples measured by assays from different

Full Text available with Trip Pro

2015 Blood Coagulation & Fibrinolysis

13. Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin (PubMed)

Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin Cancer-induced blood coagulation in human tumour generates insoluble fibrin (IF)-rich cancer stroma in which uneven monoclonal antibody (mAb) distribution reduce the potential effectiveness of mAb-mediated treatments. Previously, we developed a mAb that reacts only with IF and not with fibrinogen (FNG) or the fibrin degradation product (FDP). Although IF, FNG and FDP share same (...) amino acid sequences, the mAb is hardly neutralised by FNG and FDP in circulation and accumulates in fibrin clots within tumour tissue. Here, we created an antibody drug conjugate (ADC) using the anti-IF mAb conjugated with a chemotherapy payload (IF-ADC). The conjugate contains a linker severed specifically by plasmin (PLM), which is activated only on binding to IF. Imaging mass spectrometry showed the substantial intratumour distribution of the payload following the IF-ADC injection into mice

Full Text available with Trip Pro

2018 Scientific reports

14. The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression (PubMed)

The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression Participation of fibrin, fibrinogen, and their degradation products in pathogenesis and progression of cancer may lead to complications of thromboembolic events. The tumor may be a source of fibrinogen. Fibrinogen inside the tumor is one of the factors of its growth and metastasis. Fibrinogen, fibrin and their degradation products possess proinflammatory activity. They indirectly stimulate (...) endothelium to secrete von Willebrand factor, leading to activation of platelets accompanying neoplastic disorders. Fragments E and D are the end products of fibrin(ogen) degradation and E and DD are the end products of stabilized fibrin. E stimulates proliferation, migration and differentiation of endothelial cells, contributing to tumor vasculature. Increased levels of DD are observed in malignant neoplasms, such as breast, lung, colon and ovary cancers. In breast cancers DD correlates with progression

Full Text available with Trip Pro

2013 Contemporary Oncology

15. Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI (PubMed)

, trauma, acute brain injury, or prolonged ventilation. Plasma sGPVI was measured by enzyme-linked immunosorbent assay and was elevated on day 14 after thermal injury, and was higher in patients who developed sepsis. sGPVI levels were associated with sepsis, and the value for predicting sepsis was increased in combination with platelet count and Abbreviated Burn Severity Index. sGPVI levels positively correlated with levels of D-dimer (a fibrin degradation product) in ICU patients and patients (...) -coupled receptors by thrombin, adenosine 5'-diphosphate, or thromboxane mimetics. Enhanced fibrin production in these patients may therefore contribute to the observed elevated sGPVI levels. sGPVI is an important platelet-specific marker for platelet activation that predicts sepsis progression and mortality in injured patients.© 2018 by The American Society of Hematology.

Full Text available with Trip Pro

2018 Blood advances

16. Fibrin Degradation Products

Fibrin Degradation Products Fibrin Degradation Products Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Fibrin Degradation Products (...) Fibrin Degradation Products Aka: Fibrin Degradation Products , FDP From Related Chapters II. Normal Range: <10 ug/ml III. Increased (DIC) Primary Severe liver disease IV. False positive (RF) present Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Fibrin Degradation Products." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Fibrin split products

2015 FP Notebook

17. Clinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary study. (PubMed)

degradation products (FDP) and fibrin monomers (FM). FM was the single FGM that was significantly higher in non-surviving patients, area under the receiver-operator characteristic curve (AUCROC ): 0·617, P < 0·0001. Significantly higher International Society on Thrombosis and Haemostasis Disseminated Intravascular Coagulation (ISTH DIC) scores were calculated in non-survivors using each of the three FGMs. A dose-effect relationship was observed between ISTH DIC scores and non-survival, with highest (...) Clinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary study. An ancillary analysis to the SepsiCoag multicentric prospective observational study on patients entering an intensive care unit with septic shock evaluated the prognostic potential of fibrin generation markers (FGMs) tested at inclusion in the study, on survival at day 30. After centralization of samples, three automated FGMs were compared: D-dimers (DDi), fibrin/fibrinogen

2018 British journal of haematology

18. Analysis of the structural and mechanical effects of procoagulant agents on neonatal fibrin networks following cardiopulmonary bypass. (PubMed)

Analysis of the structural and mechanical effects of procoagulant agents on neonatal fibrin networks following cardiopulmonary bypass. Essentials The standard of care (SOC) for treating neonatal bleeding is transfusion of adult blood products. We compared neonatal clots formed with cryoprecipitate (SOC) to two procoagulant therapies. The current SOC resulted in clots with increased stiffness and decreased fibrinolytic properties. Procoagulant therapies may be a viable alternative to SOC (...) endogenous fibrin formation, we hypothesize that their addition to post-CPB neonatal plasma will better recapitulate native clot properties than cryoprecipitate. Methods We analyze the structural, mechanical and degradation properties of fibrin matrices formed by neonatal plasma collected after CPB in the presence of an activated four-factor (F) PCC (FEIBA), rFVIIa, or cryoprecipitate using confocal microscopy, atomic force microscopy and a fluidics-based degradation assay. Results The ex vivo addition

2018 Journal of Thrombosis and Haemostasis

19. Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis. (PubMed)

Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis. To elucidate the origin of the fibrin/fibrinogen degradation products (F.D.P.) occurring in the urine in glomerulonephritis 28 patients with glomerulonephritis were examined for renal fibrinolytic activity, F.D.P. in urine and serum, and blood fibrinolytic activators and blood fibrinolytic activators and inhibitors. Unlike the glomerful of healthy kidneys, which were fibrinolyticly inactive, those of kidneys (...) with glomerulonephritis constantly showed fibrinolytic activity. The presence or absence of fibrin in the glomeruli was almost always accompanied by, respectively, the presence or absence of urinary F.D.P., which suggested a renal origin of urinary F.D.P. in glomerulonephritis. The low fibrinolytic activity of the blood and the absence of F.D.P. in the serum of these patients make it unlikely that the urinary F.D.P. in glomerulonephritis result from glomerular filtration.

Full Text available with Trip Pro

1975 British medical journal

20. Serum fibrin/fibrinogen degradation products as a prognostic index in acute myocardial infarction. (PubMed)

Serum fibrin/fibrinogen degradation products as a prognostic index in acute myocardial infarction. A study of the prognostic value of serum fibrin/fibrinogen degradation products (FDP) in 137 consecutive patients with acute myocardial infarction showed a positive correlation between high FDP levels and poor prognosis. Both the frequency of complications and the mortality were related to increased levels of FDP, the highest of which were found between the fourth and eighth days after infarction.

Full Text available with Trip Pro

1975 Journal of Clinical Pathology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>